Kyungok-go for fatigue in long COVID patients: double-blind, randomized, a multi-center, pilot clinical study

INTERVENTION: Drug : For CV1 (Jeil Kyungokgo) group, take 1 pack (22.5 g) twice a day for adults before or between meals (between meals). For P (placebo) group, take 1 packet (22.5 g) twice a day before or between meals (between meals and between meals). CONDITION: Codes for special purposes PRIMARY OUTCOME: Fatigue Severity Scale (FSS) scores after herbal medicine administration for up to 12 weeks. SECONDARY OUTCOME: Analysis of target recruitment rate, dropout rate, and dropout reason for feasibility evaluation BDI (Becks’ depression inventory) score ChFS(Chalder Fatigue Scale) score and subscale score Computerized neurocognitive function test score DF(digit forward) score, DB(digit backward) score, DF‐DB score Differences in final medication adherence by herbal medicine administration group EQ‐5D‐5L score Fatigue Severity Scale (FSS) score Final medication adherence Final treatment success rate K‐MOCA(Korean‐Montreal cognitive assessment) score PSQI‐K (Korean version of Pittsburgh Sleep Quality Index) Global score Short Physical Performance Battery (SPPB) INCLUSION CRITERIA: ‐Those aged >19 years who have been diagnosed with COVID‐19 for at least 12 weeks. ‐Those who has continuously experienced fatigue for >4 weeks that they did not experience before being diagnosed with COVID‐19. ‐Those who scored >4 points on Fatigue Severity Scale (FSS) score. ‐Participants do not have any problems with overall cognitive function and voluntarily agreed to participate in the study through written consent